Roopa Industries

Roopa Industries CapEx/D&A

The CapEx to Depreciation Ratio of Roopa Industries (530991.BO) as of Nov 2, 2026 is 1.00. In the previous year, CapEx to Depreciation Ratio was 0.91 — a change of 10.06% (higher).

CapEx/D&A

1.00

YoY

10.06%

Last updated:

CapEx to Depreciation Ratio of Roopa Industries is 2025 1.00 . CapEx to Depreciation Ratio of Roopa Industries was 2024 0.91 . It decreases by 10.06% higher compared to the previous year.

The Roopa Industries CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2018
4.61 INR
Jan 1, 2019
4.68 INR
Jan 1, 2020
0.66 INR
Jan 1, 2021
0.92 INR
Jan 1, 2022
0.91 INR
Jan 1, 2023
1.54 INR
Jan 1, 2024
0.91 INR
Jan 1, 2025
1.00 INR
The Roopa Industries CapEx/D&A history
YEARCapEx/D&AYoY
1.00+10.06%
0.91-41.13%
1.54+69.17%
0.91-0.63%
0.92+39.63%
0.66-85.98%
4.68+1.43%
4.61—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Roopa Industries Stock analysis

What does Roopa Industries do? Roopa Industries Ltd. manufactures pharmaceutical products, focusing on bulk drugs and drug intermediates. The company produces N,N-dicyclohexylcarbodiimide (DCC), Triphenyl Phosphine (TPP), 5-Cyano Phthalide, Glucosamine, and Bromine And Its Derivatives. Triphenyl Phosphine is used by manufacturers of Cephalosporin antibiotics and Statins, while Bromine And Its Derivatives serve agrochemicals, dyes, medical and veterinary products, water purification, and pesticides. Glucosamine is a key nutraceutical product. The primary buyers include pharmaceutical manufacturers, agrochemical companies, and producers of medical and veterinary compounds. The company's revenue streams come from the sale of these specialized chemical products to industries requiring bulk drugs and intermediates. Triphenyl Phosphine supports antibiotic and statin production, making it essential for pharmaceutical firms. Bromine And Its Derivatives cater to diverse sectors like agriculture, water treatment, and disinfection, with significant demand from agrochemical and medical product manufacturers. Glucosamine, as a sheet anchor product, drives sales in the nutraceutical market. Roopa Industries targets the pharmaceutical, agrochemical, and medical sectors with its product portfolio. The firm's focus on bulk drugs and intermediates positions it as a supplier to manufacturers of antibiotics, statins, and nutraceuticals. Its products are integral to the production of Cephalosporin group antibiotics, Statins, and various agrochemical applications, ensuring consistent demand from established industrial buyers. Roopa Industries is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Roopa Industries stock

CapEx to Depreciation Ratio of Roopa Industries is 1.00 in 2025.

CapEx to Depreciation Ratio of Roopa Industries changed from 0.91 to 1.00, representing a 10.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Roopa Industries since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Roopa Industries with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Roopa Industries

All Key Metrics — Roopa Industries